Related references
Note: Only part of the references are listed.Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay et al.
CANCER CELL (2021)
MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate
Abbie S. Ireland et al.
CANCER CELL (2020)
The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report
Sarah M. Pearsall et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization
Marina K. Baine et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity
Kathryn L. Simpson et al.
NATURE CANCER (2020)
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
C. Allison Stewart et al.
NATURE CANCER (2020)
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Charles M. Rudin et al.
NATURE REVIEWS CANCER (2019)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer
Jing Shan Lim et al.
NATURE (2017)
A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung Cancer
Joaquim Calbo et al.
CANCER CELL (2011)
Share Paper
